Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Table 4 Risk predictors of OS in the univariate and multivariate analyses

Variable	Overall survival
	Univariate analysis		Multivariate analysis
	HR (95% CI)	P value	HR (95% CI)	P value
Age (≥55 years old vs < 55 years old)	1.247 (0.673–2.310)	0.483
AFP^a (≥400ng/ml vs < 400 ng/ml)	1.858 (1.014–3.404)	0.045^*	1.940 (1.008–3.735)	0.047^*
Ascites (Have vs None)	2.15 (1.171–3.948)	0.014^*		0.067
ECOG PS^b (0–1 vs. 2)	2.414 (1.230–4.740)	0.008^*	2.574 (1.278–5.185)	0.008^*
Child-Pugh grade (A vs B)	2.114 (1.061–4.214)	0.033^*	2.913 (1.385–6.123)	0.005^*
Arterioportal fistula (Have vs None)	1.036 (0.555–1.931)	0.912
Hemihepatic HCC^c (Yes vs. No)	0.454 (0.247–0.835)	0.011^*	0.517 (0.269–0.992)	0.047^*
HCC^c diameter (>10cm vs. ≤ 10 cm)	1.454 (0.802–2.636)	0.218
Number of tumors (Single vs. Multiple)	0.327 (0.100–1.260)	0.065
Distant metastasis (Yes vs. No)	1.829 (0.955–3.502)	0.069
Hepatic vein tumor thrombosis (Yes vs. No)	1.844 (0.850–4.003)	0.122
Cavernous transformation collateral (Yes vs. No)	0.703 (0.387–1.275)	0.246
PVTT^d type (III vs. IV)	0.801 (0.371–1.731)	0.573

ISSN: 1477-7819